Aerovate Therapeutics (AVTE) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

AVTE Stock Forecast


Aerovate Therapeutics stock forecast is as follows: an average price target of $13.00 (represents a 377.94% upside from AVTE’s last price of $2.72) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

AVTE Price Target


The average price target for Aerovate Therapeutics (AVTE) is $13.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $2.00. This represents a potential 377.94% upside from AVTE's last price of $2.72.

AVTE Analyst Ratings


Hold

According to 5 Wall Street analysts, Aerovate Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for AVTE stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 5 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Aerovate Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 17, 2024Liisa BaykoEvercore ISI$2.00$1.6521.21%-26.47%
Jun 17, 2024Eun YangJefferies$2.00$1.6521.21%-26.47%
Apr 01, 2024Tiago FauthWells Fargo$35.00$29.5718.36%1186.76%
Mar 25, 2024Eun YangJefferies$65.00$26.95141.19%2289.71%
Row per page
Go to

The latest Aerovate Therapeutics stock forecast, released on Jun 17, 2024 by Liisa Bayko from Evercore ISI, set a price target of $2.00, which represents a 21.21% increase from the stock price at the time of the forecast ($1.65), and a -26.47% decrease from AVTE last price ($2.72).

Aerovate Therapeutics Price Target by Period


1M3M12M
# Anlaysts--4
Avg Price Target--$26.00
Last Closing Price$2.72$2.72$2.72
Upside/Downside-100.00%-100.00%855.88%

In the current month, the average price target of Aerovate Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aerovate Therapeutics's last price of $2.72. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 18, 2024Wells FargoOverweightEqual-WeightDowngrade
Jun 17, 2024Cowen & Co.-HoldDowngrade
Jun 17, 2024Guggenheim-NeutralDowngrade
Jun 17, 2024Jefferies-HoldDowngrade
Jun 17, 2024BTIGBuyNeutralDowngrade
Apr 01, 2024Wells FargoOverweightOverweightHold
Dec 06, 2022BTIG-BuyUpgrade
Row per page
Go to

Aerovate Therapeutics's last stock rating was published by Wells Fargo on Jun 18, 2024. The company Downgrade its AVTE rating from "Overweight" to "Equal-Weight".

Aerovate Therapeutics Financial Forecast


Aerovate Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast$6.82M$6.79M$6.75M--------
High Forecast$6.82M$6.79M$6.75M--------
Low Forecast$6.82M$6.79M$6.75M--------
# Analysts111--------
Surprise %-----------

Aerovate Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVTE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Aerovate Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict AVTE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aerovate Therapeutics's previous annual EBITDA (undefined) of $NaN.

Aerovate Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
Net Income-----------
Avg Forecast$-17.67M$-16.48M$-15.70M$-21.00M$-3.59M$-5.18M$-7.05M$-9.49M$-11.43M$-13.42M$-23.65M
High Forecast$-17.67M$-16.48M$-15.70M$-21.00M$-3.59M$-5.18M$-7.05M$-9.49M$-11.43M$-12.74M$-23.65M
Low Forecast$-17.67M$-16.48M$-15.70M$-21.00M$-3.59M$-5.18M$-7.05M$-9.49M$-11.43M$-14.10M$-23.65M
Surprise %-----------

Aerovate Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVTE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aerovate Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Aerovate Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AVTE last annual SG&A of $NaN (undefined).

Aerovate Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts111--------
EPS-----------
Avg Forecast$-0.61$-0.57$-0.55$-0.73$-0.13$-0.18$-0.24$-0.33$-0.40$-0.47$-0.82
High Forecast$-0.61$-0.57$-0.55$-0.73$-0.13$-0.18$-0.24$-0.33$-0.40$-0.44$-0.82
Low Forecast$-0.61$-0.57$-0.55$-0.73$-0.13$-0.18$-0.24$-0.33$-0.40$-0.49$-0.82
Surprise %-----------

According to undefined Wall Street analysts, Aerovate Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AVTE previous annual EPS of $NaN (undefined).

Aerovate Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ANTXAN2 Therapeutics$1.08$8.75710.19%Buy
AVTEAerovate Therapeutics$2.72$13.00377.94%Hold
OPTOpthea$4.21$14.00232.54%Buy
ANEBAnebulo Pharmaceuticals$1.89$6.00217.46%Buy
ACRVAcrivon Therapeutics$7.85$22.00180.25%Buy
RZLTRezolute$5.44$13.50148.16%Buy
MLYSMineralys Therapeutics$13.50$30.00122.22%Buy
ADAGAdagene$3.05$5.0063.93%Buy

AVTE Forecast FAQ


No, according to 5 Wall Street analysts, Aerovate Therapeutics (AVTE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AVTE's total ratings.

Aerovate Therapeutics (AVTE) average price target is $13 with a range of $2 to $35, implying a 377.94% from its last price of $2.72. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AVTE stock, the company can go up by 377.94% (from the last price of $2.72 to the average price target of $13), up by 1186.76% based on the highest stock price target, and down by -26.47% based on the lowest stock price target.

AVTE's average twelve months analyst stock price target of $13 supports the claim that Aerovate Therapeutics can reach $4 in the near future.

Aerovate Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-25.305M (high $-25.305M, low $-25.305M), average SG&A $0 (high $0, low $0), and average EPS is $-0.88 (high $-0.88, low $-0.88). AVTE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $20.37M (high $20.37M, low $20.37M), average EBITDA is $0 (high $0, low $0), average net income is $-70.864M (high $-70.864M, low $-70.864M), average SG&A $0 (high $0, low $0), and average EPS is $-2.464 (high $-2.464, low $-2.464).